Analytical Data
-
Gene name
SLC30A2
-
简介
The SLC30A2 protein acts as an electrically neutral proton-coupled antiporter, transporting zinc ions into various intracellular organelles. SLC30A2 Protein, Human (sf9, His, MBP, FLAG) is the recombinant human-derived SLC30A2 protein, expressed by sf9 insect cells , with N-MBP, C-Flag, N-8*His labeled tag.
- Application
-
Alternative Names
SLC30A2; Zinc transporter 2; ZnT-2; Solute carrier family 30 member 2
-
Species
Human
-
Source
Baculovirus
-
Tag
N-MBP;C-Flag;N-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9BRI3
-
Expression Region
E2-D323
-
Protein Length
Partial
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SLC30A2, also known as ZnT2 (Zinc Transporter 2), encodes a protein that plays a critical role in the transport of zinc ions across cellular membranes. Zinc is an essential trace element involved in numerous biological processes, including enzyme function, protein synthesis, and immune response. Dysregulation of zinc homeostasis has been implicated in various diseases, including neurodegenerative disorders and cancer. Research on SLC30A2 has gained attention due to its association with mammary gland development and its potential role in breast cancer. In particular, mutations or alterations in the expression of SLC30A2 can lead to abnormal zinc levels, affecting cellular functions and contributing to malignancy. The recombinant protein studies of SLC30A2 provide insights into the structural and functional characteristics of this zinc transporter, facilitating the understanding of its mechanism of action and regulation. Furthermore, investigating the biochemical properties of SLC30A2 can aid in the development of therapeutic strategies aimed at restoring proper zinc balance in affected tissues. The study of SLC30A2 recombinant protein, therefore, is pivotal in elucidating the molecular underpinnings of zinc transport in health and disease, paving the way for future research and potential clinical applications.
